Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.

Diseases

Genetic and Rare Diseases Information Center (GARD)

Print friendly version

Glycogen storage disease type 13


Other Names for this Disease

  • Enolase 3 deficiency
  • Enolase-beta deficiency
  • Glycogen storage disease 13
  • GSD13
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.

Your Question

I would like to know the background, physical presentation, and diagnostic tests for glycogen storage disease type 13.  I am particularly interested in learning if hypoglycemia is part of this disease.

Our Answer

We have identified the following information that we hope you find helpful. If you still have questions, please contact us.

What is glycogen storage disease type 13?

Glycogen storage disease type 13 (GSD13), also known as β-enolase deficiency, is an inherited disease of the muscles.  The muscles of an affected individual are not able to produce enough energy to function properly, causing muscle weakness and pain.  GSD13 is caused by changes (mutations) in the ENO3 gene and is inherited in an autosomal recessive pattern.[1]
Last updated: 6/24/2012

What causes glycogen storage disease type 13?

Glycogen storage disease type 13 (GSD13) is caused by changes (mutations) in the ENO3 gene.  Glycogen is a substance that is stored in muscle tissue and is used as an important source of energy for the muscles during movement and exercise.  The ENO3 gene makes a chemical called enolase, which is an enzyme that helps the muscles use glycogen for energy.  In GSD13, the ENO3 genes do not work properly such that the body cannot make enolase, and as a result, the muscles do not have enough energy to work properly.[1]
Last updated: 6/24/2012

What are the signs and symptoms of glycogen storage disease type 13?

Glycogen storage disease type 13 causes muscle pain (myalgia).  Individuals with GSD13 also experience exercise intolerance, which means they have difficulty exercising because they may have muscle weakness and tire easily.[1]
Last updated: 6/24/2012

How is glycogen storage disease type 13 diagnosed?

Glycogen storage disease type 13 is diagnosed by taking a sample of muscle tissue (muscle biopsy) to determine if there is enough of the chemical enolase working in the muscle cells.  Genetic testing can also be done to look for changes (mutations) in the ENO3 gene.[1]
Last updated: 6/24/2012

Is hypoglycemia associated with glycogen storage disease type 13?

Unfortunately, because glycogen storage disease type 13 is very rare, there is limited information about the associated features of this condition.  However, the first individual known to have GSD13 did not have hypoglycemia.[1]
Last updated: 6/24/2012

References
  • Comi GP, Fortunato F, Lucchiari S, Bordoni A, Prelle A, Jann S, Keller A, Ciscato P, Galbiati S, Chiveri L, Torrente Y, Scarlato G, Bresolin N. Beta-enolase deficiency, a new metabolic myopathy of distal glycolysis. Annals of Neurology. 2001; 50:202-207. http://www.ncbi.nlm.nih.gov/pubmed/11506403. Accessed 6/20/2012.
Other Names for this Disease
  • Enolase 3 deficiency
  • Enolase-beta deficiency
  • Glycogen storage disease 13
  • GSD13
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.